BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
4.510
-0.050 (-1.10%)
At close: Jul 24, 2025, 4:00 PM
4.420
-0.090 (-2.00%)
After-hours: Jul 24, 2025, 6:47 PM EDT
Company Description
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases.
The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions.
BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
BioLineRx Ltd.
| Country | Israel |
| Founded | 2003 |
| IPO Date | Jul 25, 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Philip Serlin |
Contact Details
Address: Modi’in Technology Park, 2 HaMa’ayan Street Hevel Modi'in, 7177871 Israel | |
| Phone | 972 8 642 9100 |
| Website | biolinerx.com |
Stock Details
| Ticker Symbol | BLRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001498403 |
| CUSIP Number | 09071M304 |
| ISIN Number | US09071M3043 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Philip A. Serlin CPA, CPA, M.B.A., MBA | Chief Executive Officer |
| Mali Zeevi CPA, CPA | Chief Financial Officer |
| Dr. Ella Sorani Ph.D. | Chief Development Officer |
| John Lacey | Head of Corporate Communications and Investor Relations |
| Raziel Fried | Treasurer and Budgetary Control Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 30, 2025 | 6-K | Report of foreign issuer |
| May 30, 2025 | 6-K | Report of foreign issuer |
| May 27, 2025 | 6-K | Report of foreign issuer |
| May 23, 2025 | 6-K | Report of foreign issuer |
| Apr 11, 2025 | 424B5 | Filing |
| Mar 31, 2025 | 6-K | Report of foreign issuer |
| Mar 31, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Jan 21, 2025 | 6-K | Report of foreign issuer |
| Jan 17, 2025 | 6-K | Report of foreign issuer |
| Jan 10, 2025 | SCHEDULE 13G | Filing |